Wetherby Asset Management Inc. increased its holdings in shares of Eli Lilly and Co (NYSE:LLY) by 10.9% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 18,987 shares of the company’s stock after acquiring an additional 1,859 shares during the period. Wetherby Asset Management Inc.’s holdings in Eli Lilly and were worth $1,603,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Pathstone Family Office LLC raised its stake in shares of Eli Lilly and by 100.0% in the 2nd quarter. Pathstone Family Office LLC now owns 58 shares of the company’s stock valued at $4,774,000 after purchasing an additional 29 shares during the period. Vantage Financial Partners Ltd. Inc. acquired a new stake in shares of Eli Lilly and in the second quarter valued at about $494,000. Gradient Investments LLC acquired a new stake in shares of Eli Lilly and in the fourth quarter valued at about $103,000. Acrospire Investment Management LLC increased its position in shares of Eli Lilly and by 16.7% in the second quarter. Acrospire Investment Management LLC now owns 1,399 shares of the company’s stock valued at $115,000 after acquiring an additional 200 shares during the last quarter. Finally, MPS Loria Financial Planners LLC acquired a new stake in shares of Eli Lilly and in the second quarter valued at about $128,000. Institutional investors and hedge funds own 77.58% of the company’s stock.
A number of research firms recently commented on LLY. BMO Capital Markets lifted their price target on Eli Lilly and from $73.00 to $74.00 and gave the stock an “underperform” rating in a report on Thursday, February 1st. Credit Suisse Group reiterated a “hold” rating on shares of Eli Lilly and in a research report on Wednesday, December 13th. JPMorgan Chase & Co. set a $105.00 price target on shares of Eli Lilly and and gave the company a “buy” rating in a research report on Monday, February 26th. Morgan Stanley lifted their price target on shares of Eli Lilly and from $86.00 to $90.00 and gave the company an “equal weight” rating in a research report on Tuesday, November 21st. Finally, TheStreet downgraded shares of Eli Lilly and from a “b” rating to a “c” rating in a research report on Monday, March 5th. Two research analysts have rated the stock with a sell rating, eight have assigned a hold rating and ten have assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus target price of $93.47.
Shares of Eli Lilly and Co (NYSE LLY) opened at $79.15 on Wednesday. The company has a debt-to-equity ratio of 0.85, a current ratio of 1.32 and a quick ratio of 1.01. Eli Lilly and Co has a fifty-two week low of $73.69 and a fifty-two week high of $89.09. The firm has a market cap of $86,596.06, a PE ratio of 18.47, a P/E/G ratio of 1.47 and a beta of 0.28.
Eli Lilly and (NYSE:LLY) last posted its earnings results on Wednesday, January 31st. The company reported $1.14 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.08 by $0.06. The company had revenue of $6.16 billion for the quarter, compared to analyst estimates of $5.93 billion. Eli Lilly and had a negative net margin of 0.89% and a positive return on equity of 33.01%. The firm’s revenue was up 7.0% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.95 EPS. analysts expect that Eli Lilly and Co will post 4.87 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY WARNING: “Wetherby Asset Management Inc. Has $1.60 Million Position in Eli Lilly and Co (LLY)” was first reported by Week Herald and is the sole property of of Week Herald. If you are reading this article on another site, it was illegally copied and reposted in violation of U.S. and international copyright and trademark legislation. The correct version of this article can be viewed at https://weekherald.com/2018/03/14/wetherby-asset-management-inc-boosts-position-in-eli-lilly-and-co-lly.html.
Eli Lilly and Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.